Evidence map›Paper›PMID 40025278›Full record

ArticleCancer immunology, immunotherapy : CII2025

Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors.

Yuya Su, Ryo Ouchi, Pissacha Daroonpan, Miwako Hamagaki, Tohru Ikeda, Noji Rika, Naoto Nishii, Fumihiko Tsushima, Yoshihito Kano, Takahiro Asakage and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Motion-based tissueClinical and translational radiation oncology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuya Su *Department of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Ryo Ouchi *Department of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8549, Japan.
Pissacha DaroonpanDepartment of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, 113-8549, Japan.
Miwako HamagakiDivision of Surgical Pathology, Institute of Science Tokyo Hospital, Tokyo, 113-8519, Japan.
Tohru IkedaDepartment of Oral Pathology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), Tokyo, 113-8519, Japan.
Noji RikaDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Naoto NishiiDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Fumihiko TsushimaDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Yoshihito KanoDepartment of Medical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), Tokyo, 113-8519, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), Tokyo, 113-8519, Japan.
Makoto NoguchiDepartment of Oral and Maxillofacial Surgery, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, 930-0194, Japan.
Hiroyuki HaradaDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.
Miyuki AzumaDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO), 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan. miyuki.mim@tmd.ac.jp.

Funding

Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) 18H04066, 21H03138
6 · The paper itself

Abstract

objectivesAn understanding of the tumor immune microenvironment is required to improve treatment, especially the selection of immune checkpoint inhibitors (ICIs). In this study, we stratified the immunotypes of tongue squamous cell carcinoma (TSCC) based on the results of comprehensive immune profiling.

methodsWe enrolled 87 therapy-naïve TSCC and 17 ICI-treated TSCC patients who underwent glossectomy without any other prior therapy. Comprehensive immune profile analyses employed multiplex immunofluorescence and tissue imaging.

resultsBased on the hierarchies of 58 immune parameters and the spatial distances between cytotoxic T lymphocytes (CTL) and tumor cells, we stratified five immunotypes: Immunoactive type I, border type II, immunosuppressed type III, immunoisolating type IV, and immunodesert type V. The type I frequency was only 16%. Most TSCCs (~ 70%) were of types III-V. The CTL density (CTL-D) was closely correlated with the PD-L1

conclusionWe defined five TSCC-specific immunotypes based on the results of comprehensive immune profiling analyses. Immunoactive type, which would be sensitive to ICI monotherapy, was rare, and most TSCC cases exhibited immune-regulated immunotypes. Immunotype-based personalized treatments are required to improve clinical outcomes.

Indexed as

Carcinoma, Squamous CellImmune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckTongue NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisT-Lymphocytes, CytotoxicTumor MicroenvironmentImmune Checkpoint InhibitorsImmune checkpoint inhibitorImmunotherapyImmunotypesOral cancerTumor microenvironment

Identifiers

PMID40025278
PMCPMC11872838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.